Study the effect of Vitamin D3 in newly diagnosed acute myeloid leukemia

Abstract

This study is aimed to put light on the effect of vitamin D3 (VitD3) in newly diagnosed acute myeloid leukemia (AML) patients. The AML patients consisted of sixty patients (30 male, 30 female). The average age of patients was (36.44±8.44) years (range 25-45). Thirty healthy subjects were considered as controls (15 male and 15 female), and the average age of control group was (32.22±5.13) years. All subjects had to go through clinical examination to determine existence of other diseases in addition to evaluate some tests as complete blood count [hemoglobin (Hb), platelet (PLT), and white blood cells (WBCs)], ferritin, FBS (fasting blood sugar), TG (triglycerides), TC (total cholesterol), and HDL (high density lipoprotein cholesterol) (HDL-Ch), urea, and creatinine. Vitamin D3 was measured by minividase Biomerux/French. The VitD3 was highly significantly lower in AML patients than in controls (p=0.001). While, VitD3 was lower in male than in female AML patients but the difference was not statistically significant. There were statistically significant positive correlations between VitD3 and Hb, PLT, Wbc, ferritin, FBS, and TG in both male and female AML patients. These findings suggest that lower serum concentrations of vitamin D3 may possibly be considered as a potential factor for early assessment of acute myeloid leukemia.